SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : JMED - Jones Pharma (specialty pharmaceutical mfr) -- Ignore unavailable to you. Want to Upgrade?

To: Mikeh who wrote (205)2/26/1999 2:53:00 PM
From: babette spatz  Respond to of 268
 
I realized I got the number wrong. So much money lying around, the banks must love Jmed. They sure know what to do with cash. The talk of buying other companies has been going on since last Spring. Perhaps Mr. Jones stopped looking and decided to rest on past performance. I certainally would not hold on to a stock that fell significantly below the market for 10 years. Anyhow today another upgrade from DLJ, perhaps they know something.



To: Mikeh who wrote (205)3/5/1999 8:03:00 AM
From: babette spatz  Read Replies (1) | Respond to of 268
 
The "recovery" to 31 in recent days is only a small consolation. This stock is still down over 20% from last year. The company cannot keep up the the overall market valuations. As you pointed out, Mr Jones is sitting on $110 MILLION. He has not acquired companies in the aforementioned time, perhaps this explains the poor performance. He needs to perform for the shareholders. GET BUSY MR. JONES!!!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News